赛升药业：达格列净二甲双胍缓释片药品注册上市许可申请获受理

Core Viewpoint - The company has received a notice from the National Medical Products Administration regarding the acceptance of the registration application for the domestic production of Dapagliflozin Metformin Extended-Release Tablets [1] Group 1: Company Developments - The subsidiary Beijing Sai'er Biological Pharmaceutical Co., Ltd. has received the acceptance notice for the drug registration application [1] - Dapagliflozin and Metformin combination tablets were developed by AstraZeneca and were approved by the FDA in 2014 [1] Group 2: Industry Insights - SGLT-2 inhibitors work through a non-insulin-dependent mechanism, reducing glucose reabsorption in the kidneys and promoting glucose excretion through urine [1] - The combination of SGLT-2 inhibitors with Metformin has shown better glycemic control and lower side effects [1]